A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine.
- To identify genetic variation, as measured by single nucleotide polymorphisms, that is
associated with musculoskeletal adverse events in specimens from postmenopausal women
with hormone receptor-positive primary breast cancer receiving adjuvant aromatase
inhibitors and enrolled on clinical trial CAN-NCIC-MA27.
OUTLINE: This is a multicenter study.
DNA from tumor tissue and blood specimens that have been previously collected from patients
are analyzed for single nucleotide polymorphisms.
Genetic variation associated with musculoskeletal adverse events
James N. Ingle, MD
United States: Federal Government